

IN THE CLAIMS:

1. (currently amended) ~~Use of an antimuscarinic agent for the manufacture of a medicament for oral administration of a pharmaceutically effective dose of the antimuscarinic agent when needed to a mammal with unstable or overactive bladder,~~ A method for treating unstable or overactive urinary bladder in a mammal, said method comprising orally administering to a mammal a pharmaceutically effective dose of an antimuscarinic agent and when needed, whereby a symptomatic relief of urgency and/or frequency is achieved.

2. (currently amended) The ~~use~~ method as claimed in claim 1, wherein the antimuscarinic agent is one or more compounds selected from tolterodine and related compounds.

3. (currently amended) The ~~use~~ method according to claim 2, wherein the compound is tolterodine or a pharmaceutically acceptable salt thereof.

4. (currently amended) The ~~use~~ method according to claim 1, wherein the antimuscarinic agent is selected from oxybutynin, darifenacin, solifenacin, and the pharmaceutically acceptable salts and derivatives thereof.

5. (currently amended) The ~~use~~ method according to any of claims 1 to 4, wherein the mammal is human.

6. (currently amended) The ~~use~~ method according to claim 5, wherein the pharmaceutically effective dose is 2 mg or 4 mg

of the antimuscarinic agent, administered as a controlled release tablet or capsule.

7. (currently amended) The ~~use~~ method according to claim 5, wherein two pharmaceutically effective doses of the antimuscarinic agent are administered daily at an interval of within 8-12 hours.

8. (currently amended) The ~~use~~ method according to claim 7, wherein the pharmaceutically effective dose is 1 mg of the antimuscarinic agent, administered as an immediate release tablet or capsule.

9. (currently amended) The ~~use~~ method according to claim 7, wherein the pharmaceutically effective dose is 1 mg or 2 mg of the antimuscarinic agent, administered as a controlled release tablet or capsule.

10. (currently amended) The ~~use~~ method according to any of claims 1-5 or 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 8 hours.

11. (currently amended) The ~~use~~ method according to any of claims 1-5 or 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 9 hours.

12. (currently amended) The ~~use~~ method according to any of claims 1-5 or 7-9, wherein the pharmaceutically effective

doses of the antimuscarinic agent are taken within the interval of 10 hours.

13. (currently amended) The ~~use~~ method according to any of claims 1-5 or 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 11 hours.

14. (currently amended) The ~~use~~ method according to any of claims 1-5 or claims 7-9, wherein the pharmaceutically effective doses of the antimuscarinic agent are taken within the interval of 12 hours.

15. (canceled)